BriaCell Therapeutics (STU:8BT) Debt-to-EBITDA : 0.00 (As of Jan. 2024)

BriaCell Therapeutics Debt-to-EBITDA Chart

BriaCell Therapeutics Annual Data
	Trend	Jul14	Jul15	Jul16	Jul17	Jul18	Jul19	Jul20	Jul21	Jul22	Jul23
Debt-to-EBITDA		Get a 7-Day Free Trial					-0.07	-0.10	-	-	-

BriaCell Therapeutics Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Debt-to-EBITDA	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of BriaCell Therapeutics's Debt-to-EBITDA

For the Biotechnology subindustry, BriaCell Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BriaCell Therapeutics's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's Debt-to-EBITDA falls into.

BriaCell Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

BriaCell Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Jul. 2023 is calculated as

BriaCell Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Jan. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jan. 2024) EBITDA data.

BriaCell Therapeutics  (STU:8BT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

BriaCell Therapeutics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

BriaCell Therapeutics (STU:8BT) Business Description